Abbott’s Humira Approved in Europe for Expanded Treatment of Crohn’s Disease

Abbott Thursday announced that the European Commission (EC) has approved Humira (adalimumab) for the treatment of moderately active Crohn’s disease (CD) in adult patients who have had an inadequate response to conventional therapy.
Equities.com